文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

强直性脊柱炎疾病活动度的测量:患者与医生观点不同。

Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.

作者信息

Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H, van de Tempel H, van der Heijde D

机构信息

Department of Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands.

出版信息

Rheumatology (Oxford). 2005 Jun;44(6):789-95. doi: 10.1093/rheumatology/keh595. Epub 2005 Mar 9.


DOI:10.1093/rheumatology/keh595
PMID:15757962
Abstract

OBJECTIVE: There is no "gold standard" to assess disease activity in patients with ankylosing spondylitis (AS). It is known that patients and physicians have different opinions about disease activity. The objective was therefore to investigate on which criteria patients with AS and physicians base their judgement on disease activity. METHODS: A cohort of 203 AS out-patients fulfilling the modified New York criteria included in the ongoing long-term follow-up was analysed. The Assessment in Ankylosing Spondylitis (ASAS) International Working Group has established different domains relevant for outcome in AS. Each domain includes a number of instruments for making assessments, and all these instruments are included in the Outcome in Ankylosing Spondylitis International Study and were made every 6 months for 2 yr. Disease activity from the patient perspective as well as from the physician perspective was analysed using the patient's or the physician's global assessment of disease activity [visual analogue scale (VAS): 0 (best)-10 (worst)] by dichotomizing into "high disease activity" (VAS > or = 6.0) and "low disease activity" (VAS < or = 4.0). Data reduction by principal components analysis (PCA) was performed to distinguish factors capturing correlated instruments. Discriminant analysis with the factor loadings was performed to discriminate between a low and a high disease activity state from both the patient's and the physician's perspective. Multiple regression analysis on the discriminant scores was performed to prioritize the instruments. RESULTS: PCA revealed four factors: spinal mobility, physician assessments, patient assessments and laboratory assessments (Cronbach's alpha 0.52-0.80; explained variance 61%). Discriminant function analysis showed that the factor "patient assessments" was most important (pooled correlation 0.85) in discriminating between a low and a high disease activity state as defined by the patient. The other three factors contributed marginally (pooled correlation <0.30). In contrast, the factors "physician's assessments" (pooled correlation 0.62), "spinal mobility" (pooled correlation 0.52) and "laboratory assessments" (pooled correlation 0.48) contributed most to the physician's perspective. The factor "patient assessments" did not contribute at all (pooled correlation 0.05). Multivariate analysis on the discriminant scores showed that the instruments "pain spine", "BASFI", "pain joints" and "BASDAI fatigue" explained more than 90% of variance in the case of the patient perspective. The instruments "cervical rotation", "swollen joint count", "CRP" and "intermalleolar distance" explained more than 90% of variance in case of physician perspective. CONCLUSION: AS patients rate disease activity on the basis of complaints while physicians rate disease activity on the basis of instruments related to disease severity and inflammation.

摘要

目的:在强直性脊柱炎(AS)患者中,尚无评估疾病活动度的“金标准”。众所周知,患者和医生对疾病活动度的看法存在差异。因此,本研究旨在调查AS患者和医生依据哪些标准来判断疾病活动度。 方法:对正在进行长期随访的203例符合改良纽约标准的AS门诊患者进行队列分析。强直性脊柱炎评估(ASAS)国际工作组确定了与AS预后相关的不同领域。每个领域包括一些用于评估的工具,所有这些工具都纳入了强直性脊柱炎国际研究的预后评估中,并且在2年的时间里每6个月进行一次评估。从患者角度和医生角度分析疾病活动度,通过将患者或医生对疾病活动度的整体评估[视觉模拟量表(VAS):0(最佳)-10(最差)]分为“高疾病活动度”(VAS≥6.0)和“低疾病活动度”(VAS≤4.0)来进行。通过主成分分析(PCA)进行数据降维,以区分捕获相关工具的因素。利用因子载荷进行判别分析,从患者和医生的角度区分低疾病活动度状态和高疾病活动度状态。对判别分数进行多元回归分析,以对工具进行优先级排序。 结果:PCA揭示了四个因素:脊柱活动度、医生评估、患者评估和实验室评估(克朗巴哈系数0.52 - 0.80;解释方差6l%)。判别函数分析表明,在区分患者定义的低疾病活动度状态和高疾病活动度状态时,“患者评估”因素最为重要(合并相关性0.85)。其他三个因素的贡献较小(合并相关性<0.30)。相比之下,“医生评估”(合并相关性0.62)、“脊柱活动度”(合并相关性0.52)和“实验室评估”(合并相关性0.48)因素对医生的判断贡献最大。“患者评估”因素根本没有贡献(合并相关性0.05)。对判别分数的多变量分析表明,在患者角度,“脊柱疼痛”、“BASFI”、“关节疼痛”和“BASDAI疲劳”工具解释了超过90%的方差。在医生角度,“颈椎旋转度”、“肿胀关节计数”、“CRP”和“内踝间距”工具解释了超过90%的方差。 结论:AS患者根据自身主诉来评估疾病活动度,而医生则根据与疾病严重程度和炎症相关的工具来评估疾病活动度。

相似文献

[1]
Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.

Rheumatology (Oxford). 2005-6

[2]
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.

Ann Rheum Dis. 2009-1

[3]
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].

Z Rheumatol. 2003-6

[4]
Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.

Arthritis Rheum. 2006-12-15

[5]
Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity.

J Rheumatol. 1999-4

[6]
[The BASDAI-D--an instrument to defining disease status in ankylosing spondylitis and related diseases].

Z Rheumatol. 2003-6

[7]
Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.

J Rheumatol. 2004-12

[8]
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

J Rheumatol. 1999-4

[9]
Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.

Arthritis Rheum. 2007-2-15

[10]
A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments.

Ann Rheum Dis. 2004-10

引用本文的文献

[1]
Interrelationships of disease activity, central sensitization, psychosocial and lifestyle factors in axial spondyloarthritis.

Rheumatology (Oxford). 2025-6-1

[2]
Prevalence, influencing factors, and prediction model construction of anemia in ankylosing spondylitis based on real-world data: An exploratory study.

PLoS One. 2025-2-5

[3]
Correlation between clinical disease activity and sacroiliac magnetic resonance imaging detection in axial spondyloarthropathy.

Arch Rheumatol. 2024-1-29

[4]
Study on disease activity of immunological disorders to correlate with thyroid function and other associated correlations.

J Family Med Prim Care. 2024-3

[5]
Clinical value of the Patient Global Assessment with Ankylosing Spondylitis: A cross-sectional study.

Medicine (Baltimore). 2024-4-19

[6]
Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis.

Sci Rep. 2024-1-2

[7]
Factors associated with treatment intensification in patients with axial spondyloarthritis and high disease activity in clinical practice.

Rheumatology (Oxford). 2025-1-1

[8]
Assessment of axial spondyloarthritis activity using a magnetic resonance imaging-based multi-region-of-interest fusion model.

Arthritis Res Ther. 2023-11-24

[9]
The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry.

Ther Adv Musculoskelet Dis. 2023-10-9

[10]
Effect of Central Sensitization in Patients with Familial Mediterranean Fever, Axial Spondyloarthritis, and Both Diseases.

Cureus. 2023-9-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索